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Abstract
The cellular form of the prion protein (PrPC) is a normal constituent of neuronal cell membranes. The protein
misfolding causes rare neurodegenerative disorders known as transmissible spongiform encephalopathies or prion
diseases. These maladies can be sporadic, genetic or infectious. Sporadic prion diseases are the most common form
mainly affecting aging people. In this work, we investigate the biochemical environment in which sporadic prion
diseases may develop, focusing our attention on the cell membrane of neurons in the aging brain. It is well
established that with aging the ratio between the most abundant lipid components of rafts undergoes a major change:
while cholesterol decreases, sphingomyelin content rises. Our results indicate that the aging process modifies the
compartmentalization of PrPC. In old mice, this change favors PrPC accumulation in detergent-resistant membranes,
particularly in hippocampi. To confirm the relationship between lipid content changes and PrPC translocation into
detergent-resistant membranes (DRMs), we looked at PrPC compartmentalization in hippocampi from acid
sphingomyelinase (ASM) knockout (KO) mice and synaptosomes enriched in sphingomyelin. In the presence of high
sphingomyelin content, we observed a significant increase of PrPC in DRMS. This process is not due to higher levels
of total protein and it could, in turn, favor the onset of sporadic prion diseases during aging as it increases the PrP
intermolecular contacts into lipid rafts. We observed that lowering sphingomyelin in scrapie-infected cells by using
fumonisin B1 led to a 50% decrease in protease-resistant PrP formation. This may suggest an involvement of PrP
lipid environment in prion formation and consequently it may play a role in the onset or development of sporadic
forms of prion diseases.
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Introduction
The cellular form of the prion protein (PrP), PrPC, is a
glycosylphosphatidylinositol (GPI)-anchored protein present at
the surface of cells, mainly expressed in the nervous system
[1–4]. The protein was discovered due to its involvement in
prion diseases. Prions, the causative agents of these maladies,
appear in fact to be composed exclusively of a conformational
isoform of PrPC known as PrPSc. The latter contains numerous
β-sheet structures and tends to aggregate and form medium- to
large-sized polymers [5–8].
Prion diseases are a group of rare neurodegenerative
disorders that are progressive, fatal and at present incurable,
leading to death within a few months to several years. Although
the clinical profiles differ among distinct prion diseases, the
characteristics of brain damage are similar and include
extensive spongiform degeneration, widespread neuronal loss,
synaptic alterations, atypical brain inflammation and the
accumulation of protein aggregates [9]. A hallmark of prion
diseases is their etiology: they can be sporadic, genetic and
also infectious. The majority of cases are sporadic (around
85%) and the triggering factor is still unknown [10]. Sporadic
prion diseases usually affect people between the ages of 45
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and 75, and the average age of onset is around 65. The
duration of the illness varies: for most people it lasts less than a
year and may be as short as 6 weeks; in a minority of cases
the illness can last up to 3 years.
Despite over twenty years of research, several important
issues in the prion field remain unresolved. Most noticeably,
both the physiological function of PrPC and the molecular
pathways leading to fatal neurodegeneration in prion diseases
are poorly understood. Early studies on the cellular and
disease-associated PrP have determined that both forms are
tethered to cellular membranes via a GPI anchor [11]. Like
many other GPI-anchored proteins, at steady state levels PrPC
has been shown to associate predominantly with lipid rafts [12].
The precise PrPC to PrPSc conversion site is another aspect of
prion biology that is still controversial. Some studies have
reported that PrPC appears to reach its surface localization and
is subsequently internalized, leading to the conversion to PrPSc
in intracellular compartments [13]. Others, instead, have
suggested that the conversion of PrPC to PrPSc takes place in
lipid rafts. In vitro studies, using immortalized cell lines, have
shown that lipid raft composition can influence prion conversion
[14–17].
Additional investigations have reported that the ratio of major
lipid components of lipid rafts changes during aging [18,19].
Cholesterol and sphingolipids play a key role in the
organization of lipid rafts as well as in modulating their
functions. Lipid rafts act as intracellular signaling platforms and,
among other things, they are important for the differentiation
and survival pathways in neurons [20,21]. Consequently,
correct lipid homeostasis at the plasma membrane appears
essential for cell survival and functioning. Changes in the
cholesterol/sphingolipids ratio have been shown to accompany
the brain aging process, influencing cellular pathways in a
ligand-independent manner [21–25]. In agreement with these
data from in vitro and in vivo animal studies, a moderate loss of
brain cholesterol with age has also been described in humans
[18].
Abnormalities in lipid rafts have also been found in several
other diseases, including atherosclerosis, diabetes, cancer,
muscular dystrophy and neurodegenerative disorders such as
Alzheimer’s disease [26,27]. Furthermore, a deregulation of
sphingolipid metabolism with consequent membrane
disorganization has been described in several
neurodegenerative disorders [28].
Altogether these observations highlight the importance of
lipid homeostasis for the physiology of the plasma membrane
and, consequently, of the whole cell. Therefore, we decided to
investigate the effects of changes in lipid raft composition on
PrP compartmentalization and prion formation. In particular, we
focused our attention on physiological changes occurring in the
aging brain, where sporadic prion diseases are more likely to
arise in humans. We observed that variations in the
cholesterol/sphingomyelin (SM) ratio, mimicking those
occurring during aging, parallel the accumulation of PrPC in
detergent-resistant membranes (DRMs). These findings,
together with additional results obtained from scrapie-infected
cell lines, led us to hypothesize that the accumulation of PrPC
in DRMs during aging could be one of the factors triggering
sporadic prion diseases in mammals.
Materials and Methods
Mice
Ethics Statement.  All experiments were carried out in
accordance with European regulations [European Community
Council Directive, November 24, 1986 (86/609/EEC)].
Experimental procedures were notified to and approved by the
Italian Ministry of Health, Directorate General for Animal Health
(notification of 17 Sept. 2012). All experiments were approved
by the local authority veterinary service and by SISSA Ethics
Committee. Animals were killed by cervical dislocation.
Wild-type male C57BL/6J mice were obtained from the
Charles River Laboratory.
A breeding colony of acid sphingomyelinase (ASM) knockout
(KO) heterozygous C57BL/6J mice [29], kindly donated by
Edward H. Schuchman (Mount Sinai School of Medicine, New
York, NY), was established. The experiments were performed
by comparing littermates of wild-type or ASMKO mice (5
months of age); the genotype was determined from genomic
DNA in a PCR reaction.
Membrane purification from tissue
Hippocampi from C57BL/6J male mice or ASMKO mice were
dissected on ice, washed twice in cold PBS and homogenized
in 25 mM MES Buffer, pH 7.0, 5 mM DTT, 2 mM EDTA and
protease inhibitors (Roche), using a Dounce homogenizer and
10 passages through a 24-gauge syringe. Samples were
centrifuged at 700 g for 10 min at 4°C and supernatants were
considered as total extracts. A further centrifugation step was
performed at 100,000 g for 1 hour at 4°C to pellet the
membrane fraction (Optima Max Ultracentrifuge, Beckman
Instruments). The resulting pellet was re-suspended in PBS +
0.2% SDS to be subsequently processed by Western blot.
Protein concentration was determined using the Bio-Rad
Protein Microassay.
Detergent-resistant membrane purification from tissue
DRMs were prepared from total hippocampal extracts by
Triton X-100 cold extraction; soluble and insoluble fractions
were separated as described by Trovò et al. [23]. Briefly, total
protein extracts were prepared from mouse hippocampi as
described above. The protein concentration was determined
using the Bio-Rad Protein Microassay and equal amounts of
total hippocampal extracts were incubated in 25 mM MES
Buffer, pH 7.0, 5 mM DTT, 2 mM EDTA and protease inhibitors
+ 1% Triton X-100 for 1 hour at 4°C. After incubation, samples
were centrifuged at 100,000 g for 1 hour at 4°C (Optima Max
Ultracentrifuge, Beckman Instruments). The resulting DRM
pellet was re-suspended in Laemmli buffer to be processed
directly by Western blot. DRM purity was confirmed by the
presence of flotillin1 and the absence of transferring receptor 1.
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Precipitation of proteins with methanol and chloroform
Membrane proteins at low concentrations were recovered
from solutions containing high concentration of detergents or
salts through precipitation with methanol and chloroform as
described by Wessel et al. [30]. The resulting pellet was re-
suspended in PBS + 0.2% SDS or directly in Laemmli buffer for
Western blot analysis.
Western blotting
For each sample, equivalent amounts of protein were
resolved by 10% or 12% SDS-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane.
The blocking step was performed in 5% milk in Tris-buffered
saline with 0.1% Tween 20 (TBS-T) for 1 hour. Membranes
were incubated for 2 hours at room temperature or overnight at
4°C, with the corresponding primary antibodies. Afterwards,
blots were incubated with horseradish peroxidase-linked
secondary antibodies (1:10,000; Zymed Laboratories,
Invitrogen) and developed using chemiluminescence detection
(ECL, Amersham). Images were taken using a Fujifilm
LAS-3000 system and quantified with ImageJ 1.37v software
(NIH, USA).
The following primary antibodies were used: D18, humanized
monoclonal anti PrP (1:1,000; InPro Biotechnology, Inc, South
San Francisco), anti-transferrin receptor1 (1:500; Invitrogen,
Paisley, UK), mouse monoclonal anti PSD95 (1:100; Sigma),
mouse monoclonal anti Flotillin1 (1:1,000; BD Transduction),
mouse monoclonal anti Flotillin2 (1:1,000; BD Transduction),
mouse monoclonal anti α-tubulin (1:10,000; Calbiochem),
mouse monoclonal anti Vinculin (1:5,000; Sigma-Aldrich), anti
β-actin HRP conjugated (1:25,000; Sigma-Aldrich).
Preparation of functional synaptosomes
Hippocampal synaptosomes were isolated from C57BL/6J
mice following the protocol from Nagy et al. [31]. Briefly, mouse
hippocampi were dissected in ice, washed twice in cold PBS
then homogenized in 5 mM HEPES, pH 7.4, 320 mM sucrose,
1 mM EDTA using a Dounce homogenizer with 10 strokes at
200-250 rpm. The homogenate was centrifuged at 3,000 g for
10 min at 4°C and the supernatant recovered and centrifuged
again at 14,000 g for 12 min at 4°C. The resulting pellet was
carefully re-suspended in Krebs-Ringer buffer (10 mM HEPES,
pH 7.4, 140 mM NaCl, 5 mM KCl, 5 mM glucose, 1 mM EDTA),
Percoll solution was added (final concentration 45% v/v) and
the solution was mixed gently inverting the tube. After
centrifugation at 13,000 g for 2 min at 4°C, the synaptosomal
fraction was recovered at the surface of the flotation gradient
and carefully re-suspended in Krebs-Ringer buffer. The pellet
resulting from another centrifugation at 13,000 g for 30 sec at
4°C, representing the functional synaptosomal preparation,
was re-suspended in an appropriate volume of Krebs-Ringer
buffer. Synaptosomal purity was confirmed by the presence of
synaptic marker PSD95 and the absence of transferrin
receptor.
Addition of sphingomyelin to functional synaptosomes
Synaptosomal preparations from the hippocampus of a
single mouse were re-suspended in 400 µL of Krebs-Ringer
buffer and split into two 1.5 mL Eppendorf tubes.
Sphingomyelin (stock solution of 5 mg/mL in ethanol, Sigma-
Aldrich) was added in one of the tubes, at a final concentration
of 100 µg/mL; the same amount of pure ethanol was added in
the control tube. Synaptosomes were incubated in a
thermomixer at 300 rpm for 30 min at 37°C. Synaptosomes
were centrifuged at 13,000 g for 30 sec at 4°C, washed once in
Krebs-Ringer buffer and re-suspended in an appropriate
volume of 25 mM MES Buffer, pH 7.0, 5 mM dithiothreitol, 2
mM EDTA containing protease inhibitors (Roche). Protein
concentration was determined using the Bio-Rad Protein
Microassay.
Primary hippocampal cultures
Primary cultures were prepared from Wistar rat fetuses at
embryonic day 18 (E18) as described in Kaech and Banker
(2006) [32]. Animals were anaesthetized by intra peritoneal
administration of a mixture of ketamine (75 mg/kg) and xylazine
(10 mg/kg).
For biochemical analysis, 3-cm plastic dishes were coated
with 0.1 mg/mL of poly-L-lysine (PLL), overnight at 37°C.
Dissociated cells were plated at a density of 150,000 to
200,000 per dish in minimal essential medium with 10% Horse
serum (MEM-Horse). After 5-24 hours, medium was replaced
with minimal essential medium with N2 supplement (MEM-N2).
After 5 days, medium was replaced again with Neurobasal
medium with B27 supplement. Neurons were grown at 37°C
and under 5% CO2.
For microscopy experiments, cells were plated on glass
coverslips coated with 1 mg/mL of PLL, overnight at 37°C and
small paraffin dots were placed on the edges of the coverslip.
Six coverslips were placed in a 6-cm plastic dish and
dissociated cells were plated at a density of 150,000 per dish in
minimal essential medium with 10% Horse serum (MEM-
Horse). After 5-24 hours coverslips were flipped in an astrocyte
dish (neurons facing down) pre-incubated for 24 hours in
minimal essential medium with N2 supplement (MEM-N2).
Neurons were grown at 37°C and under 5% CO2.
Astrocytes were prepared from cerebral hemisphere of 1-day
old (P1) Wistar rat pups. Astrocyte cultures take 2 weeks to be
ready for use as feeder layer for neuronal cultures. Ideal
confluence of astrocytes is around 50%.
Immunolabeling of cultured neurons
Neurons grown on PLL-coated glass coverslips were fixed
with 4% p-formaldehyde, permeabilized with 0.1% Triton X-100
and treated with blocking solution (2% fetal calf serum, 2%
bovine serum albumin, and 0.2% fish skin gelatin) for 30 min at
room temperature. Then, neurons were incubated with the
primary antibodies for 60 min at room temperature. Finally,
neurons were exposed to the corresponding secondary
antibodies (1:1,000; Alexa Fluor) for 45 min. Images were
taken using a Nikon confocal microscope.
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Surface immunolabeling of cultured neurons
Neurons grown on PLL-coated glass coverslips were
incubated in their growth medium with the primary antibody of
interest for 30 min at 37°C and under 5% CO2. Dynasore
(Sigma) at a final concentration of 2.7 µL/mL was added to
block endocytosis during incubation time. Neurons were
washed twice in warm culture medium and twice in warm
HBSS prior to fixation with 4% p-formaldehyde. Neurons were
then treated with blocking solution (2% fetal calf serum, 2%
bovine serum albumin, and 0.2% fish skin gelatin) for 30 min
and subsequently exposed to the corresponding secondary
antibody (1:1,000; Alexa Fluor) for 45 min.
After surface immunolabeling, neurons were permeabilized
with 0.1% Triton X-100 and treated again with blocking solution
for 30 min at room temperature. They were subsequently
incubated with primary antibody for 60 min at room
temperature, and exposed again to the corresponding
secondary antibody (1:1,000; Alexa Fluor) for 45 min. Images
were taken using a Nikon confocal microscope.
Antibodies for immunolabeling
Recombinant anti-PrPC humanized (HuM) Fab D18 was
purchased from InPro Biotechnology, Inc, South San
Francisco. D18 was used for immunolabeling to a final
concentration of 10 µg/mL. HuM-D18 shows high affinity for
PrPC, it has a large accessibility to its specific epitope — the
region spanning residues 133-152 in the first alpha-helix of
PrPC — and binds the largest fraction of the cell-surface PrPC
population [33,34]. For co-immunolabeling experiments we
used the following antibodies: MN7.51, mouse monoclonal anti
Tau (1:10; previously described in Novak et al. [35]), rabbit
polyclonal anti MAP2 (1:500; Santa Cruz), mouse monoclonal
anti PSD95 (1:100; Sigma), mouse monoclonal anti
Synaptophisin (1:100; SySy).
Cell lines and cell culture
GT1 and ScGT1 cells were maintained in Dulbecco’s
Modified Eagle’s Medium with 4.5 g/L glucose (DMEM)
(GIBCO/Invitrogen), supplemented with 10% v/v fetal bovine
serum (GIBCO/Invitrogen) and antibiotics (100 IU/mL penicillin
and 100 mg/mL streptomycin) at 37°C in a humidified
atmosphere with 5% CO2. All cell lines were kindly provided by
Dr. P. Mellon (The Salk Institute, La Jolla, CA, USA) [36].
Scrapie cells were chronically infected with Rocky Mountain
Lab (RML) prion strain according to published procedures.
Cell culture treatment with sphingomyelin or fumonisin
B1
Both GT1 and ScGT1 cells were split 2 days before
treatment with SM or fumonisin B1 (FB1). On the second day
after splitting, the medium was refreshed and either SM or FB1
was added. SM (stock solution of 10 mg/mL in ethanol, Sigma-
Aldrich) was added at a final concentration of 100 µg/mL. The
same amount of pure ethanol was added in the control culture.
SM treatments lasted 30 minutes, 2 days and 7 days,
respectively.
FB1 (1 mM stock solution in 20 mM Hepes, Sigma-Aldrich)
was added at a final concentration of 25 µM. The same volume
of Hepes buffer was added in the control culture. Also FB1
treatment was carried on for 2 days and 7 days, respectively.
At the end of the treatment, proteins were extracted from cells
in culture to determine total PrP levels or, alternatively, for
proteinase K digestion.
Proteinase K digestion assay
ScGT1 cells were washed twice in cold PBS, lysed in lysis
buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% nonidet
P-40 substitute, 0.5% deoxycholic acid sodium salt) and
pelleted by centrifugation at 2,300 g for 5 min. The supernatant
was collected and the total protein concentration was
measured using bicinchoninic acid assay (Pierce). For the
proteinase K digestion, 250 µg of protein was treated with 2.5
µg proteinase K (Roche) for 1 hour at 37°C. Digestion was
stopped adding phenylmethyl sulphonyl fluoride at a final
concentration of 2 mM. PrP was precipitated by
ultracentrifugation at 100,000 g (Optima TL, Beckman) for 1
hour at 4°C. After centrifugation, the supernatant was
discarded and the pellet was re-suspended in Laemmli buffer
for Western blot analysis.
Statistical analysis
Comparisons between groups were performed with the
Student t test. Differences were considered significant when
p<0.05. All data are expressed as mean value ± SD and the
values of controls are adjusted to 1.
Results and Discussion
PrPC expression in vivo
Previous works have analyzed PrPC expression pattern in
the brain of several animal species by means of different
techniques [3,4]. These studies have focused mainly on PrPC
expression levels from early postnatal days to adulthood. We
decided to extend our analysis to include the postnatal
development of mouse brain, as well as adult and aging brains.
In particular, we targeted the hippocampus because: (i) PrPC is
particularly abundant in this specific brain area [3,4]; and (ii)
most PrP knockout (KO) mouse phenotypes are related to
hippocampal abnormalities [37,38].
We analyzed PrPC expression pattern at different stages of
mouse brain development: early postnatal stage (day 7),
completed synaptogenesis (1 month), full adulthood (9-10
months) and aging (23-24 months). Total membrane extracts
from mouse hippocampi were analyzed by Western blotting,
and the total amount of PrPC was considered. Typical
electrophoretic mobility of PrPC and consequently its patterning
in Western blotting is represented by 3 bands. The most
prominent band is centered at 36 kDa, a second band at 33
kDa (in some cases visible as a double band, depending on the
degree of maturation of the glycolic chain) and a less intense
one at 25 kDa. Each band represents a different glycosylation
form of the protein. In our analysis, we considered the total
amount of PrPC. In agreement with previous works [3,4], we
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observed that PrPC level in hippocampal membrane protein
extracts from wild-type mice increased at the time of
synaptogenesis (1 month), peaked during adulthood (9-10
months) and tended to remain constant during aging (20-24
months) (Figure 1).
PrPC compartmentalization on plasma membrane
during aging
Previous studies have shown that PrPC is associated for
much of its life cycle with lipid rafts, membrane domains rich in
cholesterol and glycosphingolipids [39,40]. DRMs are defined
as that part of the cellular membrane that is insoluble in cold
non-ionic detergents. Although from a biochemical standpoint
DRMs cannot be considered to correspond to in vivo rafts, they
may be used to assign raft-association when changes in DRM
composition are induced by biochemically/physiologically
relevant events.
It has been shown that the aging process is accompanied by
loss of cholesterol and increase in sphingolipids in mouse
hippocampi. Martin and colleagues showed a decrease in
cholesterol content in mouse hippocampus during development
[21,22] and the lowest levels were detected in hippocampal
membranes of aging animals (21 months old) [21,22,25].
Moreover, cholesterol decrease has been shown to parallel an
increase in SM, which reaches its highest levels in 23-month-
old animals [23]. Thus, we decided to investigate whether
changes in the two major lipid components of rafts have any
influence on PrPC association with DRMs. Comparing DRMs
from hippocampi of young adult mice (3-4 months old) with
those of aging animals (20-21 months old), we found that PrPC
levels in DRMs increased by around 30% during aging (Figure
2). No difference in total protein content was found (Figure S1).
To enhance the confidence of our results, the purity of DRM
preparations as well as the amount of PrPC associated with
detergent-soluble membranes (DSMs) were also determined
(Figures S2 and S3). Confirming previous findings, PrPC levels
in DSMs were found 30% lower in old mice than in young
animals, although this change cannot be considered
statistically significant.
Even though PrPC expression levels tend to remain constant
in the hippocampus during aging, we observed that changes in
the cholesterol/SM ratio in this brain area are accompanied by
an enrichment of PrPC in DRMs.
PrPC compartmentalization after membrane lipid
alteration
In order to test the cause-effect relationship between lipid
changes and PrPC enrichment in DRM preparations, we
analyzed PrPC compartmentalization in systems where the lipid
ratio is different from the physiological state and rather
resembles that seen during aging. We investigated systems in
which SM levels are modified or can be easily manipulated.
First we looked at PrPC compartmentalization in hippocampi
from ASMKO mice. These mice represent an animal model for
Niemann–Pick disease type A [41]. This is a suitable model for
our studies because the ASMKO neurons show anomalously
high SM levels at the plasma membrane caused by the
absence of the ASM enzyme [42]. We compared PrPC levels in
DRMs from hippocampi of wild-type and ASMKO mouse
littermates. We performed Western blotting analysis on DRM
preparations from hippocampi from 5-month-old animals. At
this developmental stage ASMKO mice are still asymptomatic
but their membranes are already enriched in SM (Figure S4). In
agreement with the hypothesized cause-effect relation, PrPC
was highly enriched in DRMs derived from ASMKOs. PrPC
levels in DRMs of ASMKO mice were 30% higher than in wild-
type littermates (Figure 3), though total protein content resulted
unchanged (Figure S5). No difference in PrPC levels was
detected in DSMs (Figure S6).
Several immuno-electron microscopy studies have shown
that PrPC is localized in synaptic boutons [43]. Therefore, to
further confirm a cause-effect relationship, we measured PrPC
levels in DRMs prepared from functional synaptosomes
exposed to SM. Purity of synaptosomal preparations was
confirmed by the presence of synaptic marker PSD95 and the
absence of transferrin receptor (Figure S7). Fresh functional
synaptosomes were incubated for 30 min at 37°C in the
presence of SM (100 µg/mL) and subsequently isolated, and
DRMs were analyzed. This acute treatment, as expected, led
to an increase in PrPC levels in DRMs, but differently from what
we had seen in previous experiments, it also increased
flotillin1, a protein used as marker for DRMs, employed to
normalize DRM blots. Considering that the treatment was
performed on the same amounts of synaptosome preparations
and the same synaptosomal preparation was compared with
and without SM treatment, we performed also a normalization
of PrP content over vinculin, a cytoskeleton-associated protein.
This allowed us to record a 35% increase in PrPC levels in
DRMs with respect to controls after SM addition (Figure 4).
We therefore showed that an increase in SM content in
cellular membranes determines accumulation of PrPC in DRMs.
This accumulation could be due to the different affinity between
the GPI-anchor and SM enriched lipid rafts with respect to
cholesterol-enriched lipid rafts.
PrPC expression and localization in vitro
The expression of PrPC and its cellular localization were
further investigated in primary rat hippocampal neurons in vitro.
We analyzed by Western blotting PrPC expression levels at
different developmental stages: before synaptogenesis (7 DIV),
after synaptogenesis (14 DIV) and in mature to aging neurons
(21 DIV) (Figure 5). The results confirmed PrPC up-regulation
over time.
To determine PrPC localization in the different cell
compartments at different developmental stages (from 3 DIV to
21 DIV) immunocytochemical experiments were performed on
cultured hippocampal neurons. This involved normal and
surface immunolabeling of PrPC coupled with different cell
markers (MAP2, Tau, PSD95 and synaptophysin). At early
stages of development, PrPC is present in all neurites, whereas
in mature neurons it is localized only in axons (Figures 6 and
7). In mature neurons, indeed, PrPC co-localizes with neurites
enriched in Tau protein and it does not co-localize with the
dendritic marker MAP2 (Figure 8). We also observed that the
pool of PrPC in mature axons is mainly restricted to the surface,
whereas in immature neurons most of the protein is still
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Figure 1.  PrPC expression levels in membrane extracts from mouse hippocampi at different developmental
stages.  Western blot analysis of equal amounts of protein from hippocampal membrane extracts (25 µg per lane) at the indicated
ages. 7 d = 7 days old; 1 m = 1 month old; 11 m = 11 months old; 23 m = 23 months old. Each lane corresponds to a single animal.
Antibodies used: D18 (1:1,000; InPro Biotechnology, Inc, South San Francisco), mouse monoclonal anti α-tubulin (1:10,000;
Calbiochem). The three major PrPC glycosylation forms are visible. Relative PrPC expression levels were analyzed from 3 to 4 mice
per time point. Each data point represents the relative protein level normalized over α-tubulin ± SD. Changes in band intensity were
analyzed and quantified with ImageJ 1.37v software (NIH, USA) followed by comparison with ANOVA test for groups of mice at
different ages. Differences were considered significant when p<0.05. PrPC levels in hippocampal membrane from mice increased
dramatically at the time of synaptogenesis (1 m), rose further during adulthood (11 m) and then remained at plateau during aging
(23 m).
n.s.: not significant, *: p<0.05, ***: p<0.001.
doi: 10.1371/journal.pone.0074244.g001
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localized in the internal cellular compartments undergoing
sorting.
To evaluate the pre/postsynaptic distribution of PrPC, we
stained mature neurons (21 DIV) with different synaptic
markers like synaptophysin (pre-synaptic marker) and PSD95
(post-synaptic marker) (Figure 9). A partial co-localization was
observed with synaptophysin, but not with PSD95.
Figure 2.  PrPC in DRM preparation of young (3-4 months) vs. old (20-21 months) mice.  Western blot analysis of DRMs
prepared from equal amounts of total hippocampal protein extracts (100 µg of total protein) at the indicated ages. Young = 3-4
months old; old = 21-22 months old. Each lane corresponds to a single animal. Antibodies used: D18 (1:1,000; InPro Biotechnology,
Inc, South San Francisco), mouse monoclonal anti flotillin1 (1:1,000; BD Biosciences). Relative PrPC amounts from 3 mice per time
point were analyzed. Each data point represents the relative protein level normalized over flotillin1 ± SD.
doi: 10.1371/journal.pone.0074244.g002
PrP in Lipid Rafts of Mouse Aging Brain
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Do changes in PrPC compartmentalization affect PrPSc
formation?
We observed that changes in the cholesterol/SM ratio
physiologically occurring during aging are accompanied by an
accumulation of PrPC in DRMs.
Several lines of evidence suggest that the conversion of
PrPC into PrPSc can be influenced by lipid raft composition
[12,15]. This phenomenon prompted us to investigate the effect
of the changes in PrPC compartmentalization on prion
formation. Recently, several cell systems permissive to the
replication of different mouse-adapted prion strains have been
developed [44]. To investigate how membrane modifications in
aging neurons affect prion formation, we used an immortalized
murine cell line derived from hypothalamic cells either
uninfected or chronically infected with RML prion strain (GT1
cells and ScGT1 cells hereafter, respectively). GT1 cells derive
from central nervous system (CNS) neurons, and they are one
of the best murine models available to investigate neurons in
vitro.
We manipulated the sphingolipid content in ScGT1 cells and
determined the effects on the formation of protease-resistant
PrPSc, a biochemical biomarker of prion infection. We analyzed
protease-resistant PrPSc formation in cells treated either with
SM or FB1, an inhibitor of sphingolipid biosynthesis.
In ScGT1 cells treated with SM (100 µg/mL) for 2 and 7
days, respectively, total PrP and protease-resistant PrPSc levels
remained unchanged (Figure S8). To investigate the effects of
SM treatment on PrPC compartmentalization, we treated non-
infected GT1 cells with SM for 30 minutes, 2 days and 7 days,
respectively (Figure S9). No significant changes in PrPC
Figure 3.  PrPC in DRMs from hippocampal membrane of young wild-type mice compared with age-matched ASMKO
mice.  Western blot analysis of DRMs prepared from equal amounts of hippocampal extracts (100 µg of protein) from young (4-5
months old) wild-type and ASMKO mice. Each lane corresponds to a single animal. Antibodies used: D18 (1:1,000; InPro
Biotechnology, Inc, South San Francisco), mouse monoclonal anti flotillin1 (1:1,000; BD Biosciences). Quantification of relative PrPC
amounts from 3 control mice and 6 ASMKO mice. Each data point represents the relative PrP level normalized over flotillin1 ± SD.
PrPC levels are 20% higher in ASMKO mice compared to age-matched wild-type mice.
**: p<0.01.
doi: 10.1371/journal.pone.0074244.g003
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 compartmentalization were observed, though the 30-minute
treatment resulted in a slight increase of PrPC in DRM
preparations. This time window does not allow for the detection
of any effect on protease-resistant PrPSc formation because it is
generally necessary to treat cells for 2 days or longer to
appreciate the effect of any drug on prion formation.
In order to relate changes in sphingolipid levels with the
formation of protease-resistant PrPSc, we treated cells with
FB1, as it inhibits the biosynthesis of sphingolipids [45,46].
Cells treated with 25 µM FB1 for 2 days did not show any
changes in either total PrP or protease-resistant PrPSc (data not
shown). On the other hand, a longer treatment (7 days) again
Figure 4.  PrPC in DRMs from functional synaptosomes treated with sphingomyelin.  Western blot analysis of DRMs prepared
from synaptosomes treated with sphingomyelin for 30 min (100 µg/mL) and relative controls. Antibodies used: D18 (1:1,000; InPro
Biotechnology, Inc, South San Francisco), mouse monoclonal anti flotillin1 (1:1,000; BD Biosciences), mouse monoclonal anti
vinculin (1:5,000; Sigma-Aldrich). Relative PrPC amounts from 3 preparations per condition. Each data point represents the relative
PrP level normalized over vinculin ± SD. Sphingomyelin treatment determined about 30% increase in PrPC levels in DRMs.
*: p<0.05.
doi: 10.1371/journal.pone.0074244.g004
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did not affect total protein levels but significantly reduced
protease-resistant PrPSc to 50% compared to controls (Figure
10). Interestingly, our findings contrast with the results obtained
by Naslavsky and colleagues using ScN2a cells [15]. This
controversial result may be due to the differences between the
cell lines used. GT1 cells are immortalized CNS neurons and
represent a model for studying changes occurring in neurons in
vitro, whereas N2a cells are cancerous cells from the
peripheral nervous system, with different characteristics
compared to CNS neurons. Because prion diseases mainly
affect the brain, we decided to use an in vitro model that
mimics CNS neurons as closely as possible
Conclusions
It has been shown that brain aging is accompanied by
changes in the cholesterol/sphingolipids ratio, thus influencing
several cellular pathways [21–25]. In particular, a moderate
loss of brain cholesterol and an increase in sphingolipids with
age have been described in several studies [21–25].
Cholesterol and sphingolipids are the major constituents of lipid
rafts, which are specialized membrane microdomains
functioning as intracellular signaling platforms. Alterations in
lipid raft composition were found in several degenerative
disorders such as atherosclerosis, diabetes, cancer, muscular
dystrophy and neurodegenerative disorders such as
Alzheimer’s disease.
In prion diseases, the sporadic forms account for
approximately 85% of all cases, mostly occurring during aging.
Being PrPC a GPI-anchored protein, it is associated with lipid
rafts, and therefore changes in lipid raft composition during
aging may greatly alter PrPC compartmentalization. In turn, this
change in localization may have consequences with regard to
PrPC physiological function and its propensity to be converted
into prions.
In this study, we first analyzed PrPC expression levels in both
murine hippocampi and rat neurons in culture at different
developmental stages. It has been established that the
expression of PrPC increases during the initial postnatal weeks
up to the synaptogenic process completion, and it remains
stable at plateau during adulthood. We found a slight decrease
in PrPC expression levels in old mice but this difference was not
statistically significant. Investigations on primary rat
hippocampal neurons in vitro confirmed a similar trend.
Interestingly, a recent investigation found that PrPC expression
levels were reduced in the hippocampus of humans during
aging and in patients with sporadic Alzheimer’s disease [47].
The discrepancy in PrPC expression levels found between
rodents and humans may reflect the different lifespan between
these species.
Figure 5.  PrPC expression levels in total protein extracts from primary neurons at different developmental stages.  Relative
PrPC amount from 3 cultures per time point. Each data point represents the mean protein level normalized over tubuline ± SD. n.s.:
not significant, *: p<0.05.
doi: 10.1371/journal.pone.0074244.g005
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In this study we found that the compartmentalization of PrPC
was affected by lipid changes occurring at the neuronal
membrane during aging. Indeed, we observed that the
decrease in cholesterol and the increase in SM that
physiologically occur in lipid rafts of hippocampal neurons in
vivo were accompanied by an enrichment of PrPC in DRMs and
its reduction in DSMs.
Using model systems that were responsive to lipid
manipulations allowed us to confirm a cause-effect relationship
between rising SM in membranes and the accumulation of
PrPC in DRMs.
The molecular mechanism by which PrPC is converted to
PrPSc relies on the direct binding between the two molecules.
An enrichment of PrPC in DRMs may favor this pathological
process. We therefore investigated how the physiological lipid
changes at the membrane of aging neurons affect prion
formation.
In our model (ScGT1) we showed that a reduction in
sphingolipid levels, which mimics a juvenile condition, inhibits
the formation of prions. This suggests an involvement of PrP-
lipid environment in prion formation and consequently in the
onset or development of sporadic prion diseases. Reduction in
cholesterol and the concomitant increase in SM trigger the
enrichment of PrPC in lipid rafts, thus favoring the likelihood of
inter-molecular contacts, and in the presence of PrPSc, these
changes lead to its pathological conversion.
Altogether, this is the first attempt to correlate membrane
lipid content, PrPC localization and prion formation at different
stages of development, adulthood and later stages of life. Our
results indicate that during aging, at least in murine models,
PrPC tends to accumulate in DRMs, a process that may lead to
higher susceptibility to prion conversion. Although additional
experiments are needed to confirm that a similar mechanism
occurs in other mammals, our results indicate a plausible
molecular basis for a higher incidence of sporadic prion
disorders in aging animals and humans.
Our findings also represent an interesting link between
aging, PrPC localization, prion diseases and Alzheimer’s
disease. PrPC has been shown to mediate Aβ oligomer toxicity
acting as a high affinity receptor [48]. PrPC-Aβ oligomers
complex formation leads to inhibition of long-term potentiation
and to memory impairments. Disruption of lipid rafts
significantly reduces the cell surface binding of Aβ oligomers,
thus preventing their toxicity [49]. Therefore, the enrichment of
PrPC into DRMs during aging, as a consequence of changes in
lipid raft composition, may increase susceptibility to prion
Figure 6.  PrPC co-immunolabeling with Tau.  Confocal images of hippocampal primary neurons at different developmental
stages. Normal (left) and surface (right) immunolabeling of PrPC (green) coupled with Tau staining (red). Antibodies used: D18 (10
µg/mL and 20 µg/mL in surface immunolabeling; InPro Biotechnology, Inc, South San Francisco), MN7.51, mouse monoclonal anti
Tau (1:10; previously described in Novak et al., 1991).
Scale bar = 10 µm.
doi: 10.1371/journal.pone.0074244.g006
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conversion as well as the binding of Aβ oligomers on cell
surface and their toxicity.
Figure 7.  PrPC co-immunolabeling with MAP2.  Confocal images of hippocampal primary neurons at different developmental
stages. Normal (left) and surface (right) immunolabeling of PrPC (green) coupled with MAP2 staining (red). Antibodies used: D18 (10
µg/mL and 20 µg/mL in surface immunolabeling InPro Biotechnology, Inc, South San Francisco), rabbit polyclonal anti MAP2
(1:500; Santa Cruz).
Scale bar = 10 µm.
doi: 10.1371/journal.pone.0074244.g007
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Figure 8.  PrPC co-immunolabeling with Tau and MAP2.  Confocal images of 21 DIV hippocampal primary neurons. Surface
immunolabeling of PrPC (green) coupled with Tau staining (red) (left) or MAP2 staining (red) (right). Antibodies used: see figures 6
and 7.
Scale bar = 10 µm.
doi: 10.1371/journal.pone.0074244.g008
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Figure 9.  PrPC co-immunolabeling with synaptophysin (left) and PSD95 (right).  Confocal images of fully developed
hippocampal primary neurons (21 DIV). Normal (above) and surface immunolabeling (below) of PrPC (green) coupled with
synaptophysin and PSD95 (red). Antibodies used: D18 (10 µg/mL and 20 µg/mL in surface immunolabeling InPro Biotechnology,
Inc, South San Francisco), mouse monoclonal anti Synaptophisin (1:100; SySy), mouse monoclonal anti PSD95 (1:100; Sigma).
Scale bar = 10 µm.
doi: 10.1371/journal.pone.0074244.g009
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Figure 10.  Total PrP and PK-resistant PrP in ScGT1 cells after treatment with FB1.  ScGT1 cells were treated for 7 days (7d)
with FB1 (25 µM). A) Western blot analysis of equal amounts of protein from ScGT1 cells (25 µg per lane). Antibodies used: D18
(1:1,000; InPro Biotechnology, Inc, South San Francisco), mouse monoclonal anti β-actin (1:25,000; Sigma-Aldrich). Each data
point represents the mean protein level normalized over β-actin ± SD.
B) Western blot analysis of equal amounts of protein from ScGT1 cells (250 µg per lane) after PK digestion. Antibodies used: D18
(1:1,000; InPro Biotechnology, Inc, South San Francisco) and mouse monoclonal anti β-actin (Sigma). Each data point represents
the mean protein level normalized over total PrP ± SD. No significant changes in PrP levels were detected in the total protein
extracts or in protease-resistant PrP after sphingomyelin treatment. FB1 treatment did not affect total PrP levels while protease-
resistant PrP decreased to 50% compared to control cultures.
n.s.: not significant, ***: p<0.001.
doi: 10.1371/journal.pone.0074244.g010
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Supporting Information
Figure S1.  Total protein content in DRMs of hippocampi
from young and aging mice. Comparison of total protein
levels in DRMs from hippocampi of young adult mice (3-4
months old) with those of aging animals (20-21 months old).
(TIF)
Figure S2.  Purity of DRM preparations. Western blot
analysis of DRM preparations. Antibodies used: anti-transferrin
receptor1 (1:500; Invitrogen, Paisley, UK), mouse monoclonal
anti Flotillin1 (1:1,000; BD Transduction), D18, humanized
monoclonal anti PrP (1:1,000; InPro Biotechnology, Inc, South
San Francisco).
(TIF)
Figure S3.  PrPC in DSM preparation of young (3-4 months)
vs. old (25 months) mice. Western blot analysis of DSMs
prepared from equal amounts of total hippocampal protein
extracts at the indicated ages. Young = 3-4 months old; old =
25 months old. Antibodies used: D18 (1:1,000; InPro
Biotechnology, Inc, South San Francisco). Relative PrPC
amounts from 3 mice per time point were analyzed. Each data
point represents the relative protein level normalized over
protein loading ± SD.
(TIF)
Figure S4.  Sphingomyelin in wild-type and ASMKO mice.
Comparison of sphingomyelin in 5-month-old wild-type and
ASMKO mice. *: p<0.05.
(TIF)
Figure S5.  Total protein content in DRMs of hippocampi
from young and ASMKO mice. Comparison of total protein
levels in DRMs from hippocampi of young adult mice (5 months
old) with those of ASMKO littermates.
(TIF)
Figure S6.  PrPC in DSMs from hippocampal membrane of
young wild-type mice compared with age-matched ASMKO
mice. Western blot analysis of DSMs prepared from equal
amounts of hippocampal extracts from young (4-5 months old)
wild-type and ASMKO mice. Antibodies used: D18 (1:1,000;
InPro Biotechnology, Inc, South San Francisco). Quantification
of relative PrPC amounts from 3 control mice and 3 ASMKO
mice. Each data point represents the relative PrPC level
normalized over protein loading ± SD.
(TIF)
Figure S7.  Purity of synaptosomal preparations. Western
blot analysis of synaptosomal preparations. Antibodies used:
PSD95 (1:100; Sigma), anti-Transferrin receptor (1:500;
13-6800 Invitrogen, Paisley, UK). Total indicates total
homogenate, and Syn indicates synaptosomes.
(TIF)
Figure S8.  Total PrP and PK-resistant PrP in ScGT1 cells
after treatment with SM. ScGT1 cells were treated for 7 days
(7d) with sphingomyelin (100 µg/mL). A) Western blot analysis
of equal amounts of protein from ScGT1 cells (25 µg per lane).
Antibodies used: D18 (1:1,000; InPro Biotechnology, Inc, South
San Francisco), mouse monoclonal anti β-actin (1:25,000;
Sigma-Aldrich). Each data point represents the mean protein
level normalized over β-actin ± SD. B) Western blot analysis of
equal amounts of protein from ScGT1 cells (250 µg per lane)
after PK digestion. Antibodies used: D18 (1:1,000; InPro
Biotechnology, Inc, South San Francisco) and mouse
monoclonal anti β-actin (Sigma). Each data point represents
the mean protein level normalized over total PrP ± SD. No
significant changes in PrP levels were detected in the total




Figure S9.  PrPC in DRMs from GT1 cells treated with
sphingomyelin. Western blot analysis of DRMs prepared from
equal amounts of protein (150 µg of total protein) from GT1
cells treated with 100 µg/ml of sphingomyelin. A) GT1 cells
treated for 2 days (2d). B) GT1 cells treated for 7 days (7d). C)
GT1 cells treated for 30 minutes (30m). Antibodies used: D18
(1:1,000; InPro Biotechnology, Inc, South San Francisco),
mouse monoclonal anti flotillin2 (1:1,000; BD Biosciences).
Each data point represents the mean protein level normalized
over flotillin2 ± SD. No significant changes in PrP levels could
be detected in the DRMs after sphingomyelin long treatment
(2d or 7d). After short treatment (30m) PrP showed a tendency
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